Cargando…

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kian, Waleed, Christopoulos, Petros, Remilah, Areen A., Levison, Esther, Dudnik, Elizabeth, Shalata, Walid, Krayim, Bilal, Marei, Ranin, Yakobson, Alexander, Faehling, Martin, Kahala, Dolev, Sara Granot, Inbal, Levitas, Dina, Peled, Nir, Roisman, Laila C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531269/ https://www.ncbi.nlm.nih.gov/pubmed/36203432 http://dx.doi.org/10.3389/fonc.2022.1010311

Ejemplares similares

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer
por: Kian, Waleed, et al.
Publicado: (2020)

An Unusual Presentation of HCC in a Patient with No Underlying Liver Disease: A Case Study
por: Osyntsov, Anton, et al.
Publicado: (2022)

Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy
por: Yakobson, Alexander, et al.
Publicado: (2021)

Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study
por: Kian, Waleed, et al.
Publicado: (2022)

Associated Myocarditis: A Predictive Factor for Response?
por: Shalata, Walid, et al.
Publicado: (2020)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
por: Imran, Mohd, et al.
Publicado: (2021)

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
por: Garcia Campelo, Maria Rosario, et al.
Publicado: (2022)

1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options
por: Zemel, M., et al.
Publicado: (2021)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
por: Shalata, Walid, et al.
Publicado: (2023)

Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
por: Yakobson, Alexander, et al.
Publicado: (2023)

Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022)

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
por: Wang, Jun, et al.
Publicado: (2022)

The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations
por: Hernandez, Luis, et al.
Publicado: (2023)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs
por: Iraqi, Muhammed, et al.
Publicado: (2022)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination
por: Shalata, Walid, et al.
Publicado: (2022)

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
por: Zhou, Caicun, et al.
Publicado: (2021)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
por: Szeto, Chun Ho, et al.
Publicado: (2021)

Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer
por: Roisman, Laila C., et al.
Publicado: (2023)

Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
por: Kian, Waleed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u3j6fl09cfh6ef27ors2mb770j